诺和诺德欧股涨超3%

Core Viewpoint - Novo Nordisk's stock price increased by over 3% following a real-world study on heart disease, where its drug Wegovy outperformed Eli Lilly's Zepbound [1] Company Summary - Novo Nordisk's Wegovy demonstrated superior results in a study focused on heart disease compared to Eli Lilly's Zepbound, contributing to the rise in its stock price [1]